María Teresa Alvarez-Román, MD, PhD

Head of the Thrombosis and Haemostasis Unit
La Paz University Hospital, Madrid, Spain

Professor Maria Teresa Álvarez Román is the Head of the Haemostasis Unit at the University Hospital La Paz, Madrid, Spain.
She studied Medicine at the University of Salamanca, Spain. After completing the Haematology residency at Hospital La Paz, she obtained her PhD at the Autonomous University of Madrid with a research project on platelets.

Associate Professor. School of Medicine. Autonomous University. Madrid.
Executive Master in management of Health Organizations at ESADE Business School.
She is a researcher of the “Coagulopathy and haemostasis diseases group” of La Paz Research Institute (IdiPaz), focused on Research, Development and Innovation.
Member of the committee of experts for the development of the “Therapeutic Guide for Hemophilia Patients”, Spanish Ministry of Health.
Director of the Master Degree titled “Master on congenital and acquired coagulopathies”, University of Alcala, Madrid. Director of the annual training course titled “Conference on hemostasis: from physiology to pathology”, International University of Andalucia, Spain.
She completed a Postgraduate Training Course on thrombotic pathology.
She is involved in a great number of clinical trials and has received several national and international awards in the scope of hemophilia and other congenital coagulation disorders.
More than 60 manuscripts and more than 30 chapters related to the specialty.
Member of the Scientific Advisory Council of the PedNet group.
President of the Scientific Committee of the Victoria Eugenia Foundation.
Member of the Scientific Committee of the Spanish Society of Thrombosis and Haemostasis.
Member of EAHAD Executive Committee

Presentation(s):

• OC 27.4 - Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A - results from A-SURE, a 24-month prospective, non-interventional study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM

• PB0193 - Dose optimization for prophylaxis using a pharmacokinetic model for factor IX products in severe hemophilia B

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0536 - Ex vivo study of the concomitant use of plasma-derived Factor VIII/Von Willebrand Factor and emicizumab in patients with severe Hemophilia A

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1054 - Evaluation of platelet function in rare or undiagnosed bleeding disorders

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1123 - Annualised Bleeding Rate and Joint Health: Second Interim Analysis of the Real-world HEM-POWR Study Evaluating the Effectiveness of Damoctocog Alfa Pegol in Patients With Haemophilia A

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1172 - Impact of inhibitors on the procoagulant efficacy of bypass agents or hemostatic factors in combination with emicizumab

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1174 - Eptacog beta for resolution of bleeding episodes in patients with hemophilia A or B with inhibitors: Efficacy and safety according to inhibitor titer

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1206 - Effect of agonists to thrombopoietin receptors on platelet glycome of patients with immune thrombocytopenia

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1208 - Discontinuation of thrombopoietin receptor agonists: a 10 year real-world experience from an academic hospital in Madrid

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1238 - Effect of constitutive activation of the calcium sensor STIM1 on haemostasis

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM